Reaction
Hormone Receptor Positive Breast Cancer reporting signals
As of the last recalculation, Hormone Receptor Positive Breast Cancer appears in 260 FAERS reports alongside 14 co-occurring drug terms. The strongest observed disproportionality signal is EXEMESTANE (PRR 131.4).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Exemestane | 31 | 131.4 | 131.6 |
| Letrozole Tablets | 57 | 121.2 | 121.4 |
| Everolimus Tablets | 23 | 120.4 | 120.5 |
| Letrozole | 59 | 98.9 | 99.0 |
| Ribociclib | 32 | 92.4 | 92.5 |
| Goserelin | 13 | 81.5 | 81.6 |
| Fulvestrant | 27 | 72.9 | 73.0 |
| Anastrozole Tablets | 16 | 63.5 | 63.6 |
| Lapatinib | 11 | 59.2 | 59.3 |
| Ado-Trastuzumab Emtansine | 6 | 58.3 | 58.3 |
| Everolimus | 27 | 47.3 | 47.3 |
| Alpelisib | 3 | 27.9 | 27.9 |
| Diroximel Fumarate | 4 | 27.3 | 27.3 |
| Levonorgestrel | 25 | 10.9 | 10.9 |